格隆汇2月10日丨国科天成(301571.SZ)公布，大数成长计划自减持公告披露之日起十五个交易日后的连 续90个自然日内，以集中竞价和/或大宗交易方式减持持有的公司股份不超过3%，其中通过集中竞价交 易减持股份的总数，不超过公司股份总数的1%；通过大宗交易减持股份的总数，不超过公司股份总数 的2%。 ...

格隆汇2月10日丨国科天成(301571.SZ)公布2025年度业绩快报，报告期内，公司实现营业收入11亿元， 较上年同期增长14.73%；实现归属于上市公司股东的净利润2.04亿元，较上年同期增长17.94%。报告期 内影响经营业绩及主要财务指标变动的原因有：1、报告期内，公司在红外光电领域积极布局，制冷红 外继续发挥行业地位和品牌优势，非制冷红外和光学产品快速突破；2、公司紧跟市场需求，积极开拓 业务，订单充足，产量提升；3、公司加大技术研发与创新，提升生产自动化水平，促进公司整体经济 效益提升。 ...

Summary of Key Points Core Viewpoint - Huazhong Xinchang (300928.SZ) announced that Vice President Zhang Long plans to reduce his shareholding in the company by a maximum of 24,900 shares, which represents 0.03% of the total share capital, within three months from March 11, 2026, to June 10, 2026, through centralized bidding [1] Company Actions - The planned share reduction will occur within a specified timeframe of three months [1] - The method of share reduction will be through centralized bidding, including after-hours pricing [1] Shareholding Details - The total number of shares Zhang Long intends to sell is 24,900 [1] - This reduction accounts for 0.03% of the company's total share capital [1]

Core Viewpoint - Xu Jiahui (002561.SZ) announced that its wholly-owned subsidiary, Shanghai New Six Hundred Commercial Management Co., Ltd., plans to sign a lease agreement with its controlling shareholder, Shanghai Xu Jiahui Mall (Group) Co., Ltd., through its wholly-owned subsidiary, Shanghai Xu Jiahui Mall Group Commercial Development Co., Ltd. [1] Group 1 - The lease will involve a property located at 932 Hengshan Road, which is owned by the commercial development company [1] - The business will operate under the name "New Six Hundred YOUNG" [1] - This transaction is classified as a related party transaction [1]

Group 1 - The company planned to acquire 100% equity of Hangzhou Gao Ye Jia You Duo Mao Pet Food Co., Ltd. through a combination of issuing shares and cash payments to 19 transaction parties [1] - The company intended to raise supporting funds by issuing shares to no more than 35 qualified specific objects [1] Group 2 - Since the announcement of the transaction, the company has been actively organizing the transaction work in accordance with relevant laws and regulations [2] - Various intermediary institutions have been engaged to conduct due diligence, preliminary audits, legal compliance checks, and initial valuation assessments of the target company [2] - Due to changes in the target company's sales model for cat litter and the initial investment in promoting new cat food, the company's operational situation in 2025 deviated from initial expectations, leading to a failure to reach consensus on core commercial terms with the transaction parties [2] - As a result of careful consideration and negotiations, the company decided to terminate the transaction and signed a termination agreement with the transaction parties [2]

Core Viewpoint - Yuxin Co., Ltd. (002986.SZ) announced an employee stock ownership plan for 2026, with a total funding amount not exceeding 8.20845 million yuan, sourced from self-raised funds, own funds, and employees' legal salaries [1] Group 1: Employee Stock Ownership Plan Details - The employee stock ownership plan will involve participation from the company's directors, senior management, and core employees, totaling no more than 21 individuals, with the exact number depending on actual employee circumstances [1] - The company's board of directors has the authority to adjust the list of participating employees and the allocation ratio based on employee changes and performance assessments [1] - The stock source for this plan will be from the company's repurchase special securities account, totaling no more than 1.305 million shares, which accounts for approximately 0.34% of the company's total existing share capital [1] Group 2: Stock Purchase Price - The purchase price for the repurchased shares under the employee stock ownership plan is set at 6.29 yuan per share [1]

公司研发的本疫苗为采用水痘-带状疱疹病毒（Varicella-zoster virus,VZV）减毒株接种人二倍体细胞， 经冻干工艺制成的减毒活疫苗。接种本疫苗后，可刺激机体产生抗水痘-带状疱疹病毒的免疫力，用于 预防水痘。 格隆汇2月10日丨沃森生物(300142.SZ)公布，由云南沃森生物技术股份有限公司及子公司云南疫苗实验 室有限公司、北京沃森创新生物技术有限公司和玉溪沃森生物技术有限公司联合研发并共同申请临床试 验的水痘减毒活疫苗，于近日获得国家药品监督管理局签发的《药物临床试验批准通知书》。通知书编 号为：2026LP00378。注册分类：预防用生物制品。审批结论：根据《中华人民共和国药品管理法》 《中华人民共和国疫苗管理法》及有关规定，经审查，2025年11月20日受理的水痘减毒活疫苗符合药品 注册的有关要求，同意开展预防水痘的临床试验。药物临床试验应当自批准之日起3年内实施，3年内未 有受试者签署知情同意书的，本件自行失效。 ...

Group 1 - The company, Chutianlong (003040.SZ), plans to issue shares to specific investors to raise a total of up to 760 million yuan [1] - The net proceeds from the fundraising, after deducting issuance costs, will be used for the research and industrialization of innovative application security products [1] - The funds will also support the construction of smart hardware projects for industry applications, the establishment of a digital operation headquarters, and upgrades to research and development [1] - Additionally, the funds will be used to supplement working capital [1]

Core Viewpoint - The stock of the company experienced a significant price fluctuation, with a cumulative increase of over 20% over three consecutive trading days, triggering abnormal trading activity [1] Group 1: Stock Performance - The stock price increased by more than 20% from February 6 to February 10, 2026, with trading volumes showing turnover rates of 12.74%, 16.98%, and 27.26% respectively [1] Group 2: Company Operations - The company conducted a self-examination of its main business, business model, and operational status, confirming that everything is normal [1] - The controlling shareholder and actual controller do not have any undisclosed significant information [1] Group 3: Shareholder Actions - The company's director and president, Pan Xinxin, along with the financial director, Wang Xiaoying, plan to reduce their holdings by a total of no more than 177,300 shares, which represents 0.0657% of the total shares [1] - This share reduction plan is scheduled to take place between March 5 and June 4, 2026, but has not yet been implemented [1]

Core Viewpoint - Yuxin Co., Ltd. (002986.SZ) announced a stock option incentive plan for 2026, aiming to grant up to 4.0176 million stock options, which represents approximately 1.06% of the company's total share capital at the time of the announcement [1] Summary by Categories - **Incentive Plan Details** - The incentive plan will grant stock options to a total of 293 individuals [1] - The exercise price for the stock options (including reserved portions) is set at 10.07 yuan per share [1]